Literature DB >> 8486781

Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.

D M Lanese1, J D Conger.   

Abstract

Recent evidence suggests that the potent constrictor peptide, endothelin (ET) has a mediating role in cyclosporine A (CsA)-related renal vasoconstriction. However, the nature of the CsA-ET interaction and effect on the renal vasculature is uncertain. The purpose of the present study was twofold: (a) to determine if CsA exposure caused direct local release of ET from the endothelium of the renal microvasculature and (b) to determine if locally generated ET has paracrine effects on the underlying vascular smooth muscle to induce vasoconstriction. Experiments were performed in isolated rat renal arterioles. First it was determined that both afferent arteriole (AA) and efferent arteriole (EA) exhibited concentration-dependent decreases in lumen diameter to increasing molar concentrations of CsA. The AA was more sensitive to the vasoconstrictive effects of CsA than the EA. Next, the blocking effect of a recently synthesized putative ETA receptor antagonist was verified in both the AA and EA, where it was found that the cyclic peptide cyclo D-Asp-L-Pro-D-Val-L-Leu-D-Trp totally inhibited the vasoconstriction observed with ET addition. Finally, the role of locally stimulated ET in CsA-induced vasoconstriction was tested by determining the effect of the ETA receptor antagonist on CsA-induced AA and EA constriction. In the AA the vasoconstrictor effect of 10(-11) M CsA was completely blocked by the ETA receptor antagonist. However, in contrast to AA, 10(-11) M CsA in EA in the presence of the ETA receptor antagonist decreased EA lumen diameter by a mean of 41% from baseline (4.80 +/- 0.75 microns vs 7.80 +/- 0.84 microns, P < 0.05). This change in lumen diameter was similar to that induced by CsA alone. These data suggest that CsA directly constricts renal microvessels. This effect is mediated by ET in the AA but not the EA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486781      PMCID: PMC288216          DOI: 10.1172/JCI116440

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.

Authors:  C Smeesters; P Chaland; L Giroux; J M Moutquin; P Etienne; F Douglas; J Corman; G St-Louis; P Daloze
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

2.  Effect of cyclosporine A treatment on vascular reactivity of the rat thoracic aorta.

Authors:  A Rego; R Vargas; M L Foegh; P W Ramwell
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

3.  Cyclosporine and urinary prostaglandins.

Authors:  T L Kho; J Teule; K M Leunissen; G A Heidendahl; P Lijnen; A Amery; J P van Hooff
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

4.  Effects of cyclosporine on renal hemodynamics and autoregulation in rats.

Authors:  F J Kaskel; P Devarajan; L A Arbeit; L C Moore
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

5.  Cyclosporine-induced nephrotoxicity: pathophysiology of decreased blood flow.

Authors:  J J Curtis; D A Laskow
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

6.  Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats.

Authors:  N G Moss; S L Powell; R J Falk
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  Effect of cyclosporine administration on renal hemodynamics in conscious rats.

Authors:  B M Murray; M S Paller; T F Ferris
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

8.  Some statistical methods useful in circulation research.

Authors:  S Wallenstein; C L Zucker; J L Fleiss
Journal:  Circ Res       Date:  1980-07       Impact factor: 17.367

9.  Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity.

Authors:  E J Barros; M A Boim; H Ajzen; O L Ramos; N Schor
Journal:  Kidney Int       Date:  1987-07       Impact factor: 10.612

10.  Comparative sensitivities of isolated rat renal arterioles to endothelin.

Authors:  D M Lanese; B H Yuan; I F McMurtry; J D Conger
Journal:  Am J Physiol       Date:  1992-11
View more
  39 in total

Review 1.  Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation.

Authors:  Pratima Sharma; Khurram Bari
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

2.  Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient.

Authors:  Eswari Vilayur; Jillian de Malmanche; Paul Trevillian; David Ferreira
Journal:  BMJ Case Rep       Date:  2018-12-13

Review 3.  Renal complications following lung and heart-lung transplantation.

Authors:  Paul D Robinson; Rukshana C Shroff; Helen Spencer
Journal:  Pediatr Nephrol       Date:  2012-06-24       Impact factor: 3.714

Review 4.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

5.  Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.

Authors:  M Lassila; P Finckenberg; A K Pere; L Krogerus; J Ahonen; H Vapaatalo; M L Nurminen
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 6.  Role of endothelin in hypertension.

Authors:  B K Krämer; M Ackermann; S M Kohler; G A Riegger
Journal:  Clin Investig       Date:  1994-01

7.  Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats.

Authors:  Atsushi Yamauchi; Ryozo Oishi; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2004-10       Impact factor: 5.046

8.  RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity.

Authors:  A Siedlecki; J R Anderson; X Jin; J R Garbow; T S Lupu; A J Muslin
Journal:  Am J Transplant       Date:  2009-12-02       Impact factor: 8.086

Review 9.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 10.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.